Corrigendum: Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738

Understanding the therapeutic effect of drug dose and scheduling is critical to inform the design and implementation of clinical trials. The increasing complexity of both mono, and particularly combination therapies presents a substantial challenge in the clinical stages of drug development for oncology. Using a systems pharmacology approach, we have extended an existing PK-PD model of tumor growth with a mechanistic model of the cell cycle, enabling simulation of mono and combination treatment with the ATR inhibitor AZD6738 and ionizing radiation. Using AZD6738, we have developed multi-parametric cell based assays measuring DNA damage and cell cycle transition, providing quantitative data suitable for model calibration. Our in vitro calibrated cell cycle model is predictive of tumor growth observed in in vivo mouse xenograft studies. The model is being used for phase I clinical trial designs for AZD6738, with the aim of improving patient care through quantitative dose and scheduling prediction.

[1]  Thierry Dorval,et al.  HCS-Analyzer: open source software for high-content screening data correction and analysis , 2012, Bioinform..

[2]  B. Ploeger,et al.  Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. , 2008, Trends in pharmacological sciences.

[3]  Galit Lahav,et al.  Dynamics of the DNA damage response: insights from live-cell imaging. , 2013, Briefings in functional genomics.

[4]  S. Elledge,et al.  The DNA damage response: making it safe to play with knives. , 2010, Molecular cell.

[5]  N Benson,et al.  Reducing systems biology to practice in pharmaceutical company research; selected case studies. , 2012, Advances in experimental medicine and biology.

[6]  B. Zhivotovsky,et al.  Death through a tragedy: mitotic catastrophe , 2008, Cell Death and Differentiation.

[7]  Ran Kafri,et al.  Quantitative live cell imaging reveals a gradual shift between DNA repair mechanisms and a maximal use of HR in mid S phase. , 2012, Molecular cell.

[8]  Neil Benson,et al.  Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development , 2011, Pharmaceutical Research.

[9]  J. Bartek,et al.  More than just a focus: The chromatin response to DNA damage and its role in genome integrity maintenance , 2011, Nature Cell Biology.

[10]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.

[11]  Ji-Hoon Lee,et al.  Direct Activation of the ATM Protein Kinase by the Mre11/Rad50/Nbs1 Complex , 2004, Science.

[12]  Paolo Sassone-Corsi,et al.  Timing the cell cycle , 2003, Nature Cell Biology.

[13]  Ken Ito,et al.  An Integrated Computational/Experimental Model of Lymphoma Growth , 2013, PLoS Comput. Biol..

[14]  Lye Mun Tho,et al.  The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. , 2010, Advances in cancer research.

[15]  Abdelghani Mazouzi,et al.  DNA replication stress: causes, resolution and disease. , 2014, Experimental cell research.

[16]  L. Zou,et al.  ATR: a master conductor of cellular responses to DNA replication stress. , 2011, Trends in biochemical sciences.

[17]  W. Jusko,et al.  Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells , 2013, Cancer Chemotherapy and Pharmacology.

[18]  J. Nickoloff,et al.  Regulation of DNA double-strand break repair pathway choice , 2008, Cell Research.

[19]  David S. Broomhead,et al.  A systematic survey of the response of a model NF-κB signalling pathway to TNFα stimulation , 2012, Journal of theoretical biology.

[20]  John J. Tyson,et al.  Modeling the Cell Division Cycle: M-phase Trigger, Oscillations, and Size Control , 1993 .

[21]  Jiri Bartek,et al.  Cell-cycle checkpoints and cancer , 2004, Nature.

[22]  E. Kass,et al.  Collaboration and competition between DNA double‐strand break repair pathways , 2010, FEBS letters.

[23]  Ruedi Aebersold,et al.  Beyond ATM: The protein kinase landscape of the DNA damage response , 2011, FEBS letters.

[24]  T. Paull,et al.  Ataxia Telangiectasia-Mutated (ATM) Kinase Activity Is Regulated by ATP-driven Conformational Changes in the Mre11/Rad50/Nbs1 (MRN) Complex* , 2013, The Journal of Biological Chemistry.

[25]  Pablo Huertas Sánchez,et al.  Regulation of DNA double strand break repair pathways , 2013 .

[26]  Jiri Bartek,et al.  ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks , 2006, Nature Cell Biology.

[27]  P. I. Barton,et al.  Efficient sensitivity analysis of large-scale differential-algebraic systems , 1997 .

[28]  J. Tyson,et al.  Design principles of biochemical oscillators , 2008, Nature Reviews Molecular Cell Biology.

[29]  Marco Foiani,et al.  Regulation of DNA repair throughout the cell cycle , 2008, Nature Reviews Molecular Cell Biology.

[30]  J. Greef,et al.  Rescuing drug discovery: in vivo systems pathology and systems pharmacology , 2005, Nature Reviews Drug Discovery.

[31]  M. Cuadrado,et al.  "ATR activation in response to ionizing radiation: still ATM territory" , 2006, Cell Division.

[32]  Neil D. Evans,et al.  Modelling of tumour growth and cytotoxic effect of docetaxel in xenografts , 2014, Comput. Methods Programs Biomed..

[33]  Klaus Schittkowski.  Computational Mathematical Programming , 2011 .

[34]  Kok Lay Teo,et al.  Control parametrization: A unified approach to optimal control problems with general constraints , 1988, Autom..

[35]  J. Wagner.  Pharmacokinetics for the Pharmaceutical Scientist , 1993 .

[36]  Shea N Gardner,et al.  Cell Cycle Phase-Specific CHemotherapy: Computation Methods for Guiding Treatment , 2002, Cell cycle.

[37]  Steven W. Martin,et al.  The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. , 2007, Drug discovery today.

[38]  D J Greenblatt,et al.  Pharmacokinetics and pharmacodynamics. , 1990, Hospital practice.

[39]  Stéphanie Panier,et al.  Double-strand break repair: 53BP1 comes into focus , 2013, Nature Reviews Molecular Cell Biology.

[40]  M. Danhof,et al.  Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling—A New Classification of Biomarkers , 2005, Pharmaceutical Research.

[41]  K. Khanna.  Cancer risk and the ATM gene: a continuing debate. , 2000, Journal of the National Cancer Institute.

[42]  M. Nowak,et al.  Linear Model of Colon Cancer Initiation , 2004, Cell cycle.

[43]  John J Tyson,et al.  Mathematical modeling as a tool for investigating cell cycle control networks. , 2007, Methods.

[44]  Albert Goldbeter,et al.  An automaton model for the cell cycle , 2011, Interface Focus.

[45]  E. Rogakou,et al.  Histone H2A variants H2AX and H2AZ. , 2002, Current opinion in genetics & development.

[46]  S. Guichard,et al.  Abstract 2348: Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients. , 2013 .

[47]  N Benson,et al.  Model‐Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development , 2013, Clinical pharmacology and therapeutics.

[48]  J. Tyson.  Modeling the cell division cycle: cdc2 and cyclin interactions. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[49]  D. Lauffenburger,et al.  Computational modeling of the EGF-receptor system: a paradigm for systems biology. , 2003, Trends in cell biology.

[50]  B. Barlogie,et al.  Further biologic characteristics of a human carcinoembryonic antigen-producing colon carcinoma cell line. , 1978, Journal of the National Cancer Institute.

[51]  F. Bruggeman,et al.  Cancer: a Systems Biology disease. , 2006, Bio Systems.

[52]  A. Balan,et al.  Radiation Induced Oral Mucositis , 2009, Indian journal of palliative care.